Navigation Links
Monogram and Dana-Farber Cancer Institute Initiate Evaluation of HERmark(TM) Breast Cancer Assay in Metastatic Breast Cancer
Date:9/23/2008

SOUTH SAN FRANCISCO, Calif., Sept. 23 /PRNewswire-FirstCall/ -- Monogram Biosciences, Inc. (Nasdaq: MGRM) announced today that it has initiated a study, in collaboration with the Dana-Farber Cancer Institute (DFCI), to evaluate Monogram's HERmark(TM) Breast Cancer Assay in metastatic breast cancer.

In the study, Monogram's proprietary HERmark assay will be used to analyze approximately 600 tissue samples from patients with breast cancer, approximately half of whom were eligible for treatment with Herceptin(R) on the basis of prior HER2 IHC and/or FISH testing. HERmark measurements of HER2 total protein and HER2 homodimer levels will be compared with the results of IHC and/or FISH testing as well as response to treatment with Herceptin.

"Results from prior studies in metastatic breast cancer have suggested that HERmark can identify subsets of patients with different responses to Herceptin even though they had all been previously assessed as 'HER2-positive' by IHC and/or FISH, tested centrally," said Michael Bates, M.D., Monogram's Vice President of Clinical Research. "The aim of this study is to test the hypothesis that HERmark selects patients for Herceptin treatment in the metastatic setting better than other currently available assays, as well as to test cutoff values that have been previously defined for HERmark. In addition, we will also measure HER3 expression levels in these tumors and see if they correlate with clinical outcomes in this cohort. The study will also provide enough tissue to facilitate testing of assays that are in advanced development at Monogram, including assays for HER1 expression, p95 expression, as well as heterodimers of HER2, such as HER2:HER3 and HER1:HER2."

"The VeraTag technology repres
'/>"/>

SOURCE Monogram Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2008
2. Monogram Biosciences Launches First Resistance Assay for HIV Integrase Inhibitors
3. Monogram Biosciences Announces Second Quarter 2008 Financial Results Conference Call
4. Monogram Biosciences to Present at the Collins Stewart Fourth Annual Growth Conference
5. Sensitivity Enhancements to Monograms Trofile(TM) Assay Demonstrate Improved Power to Select Patients for CCR5 Antagonist Therapy
6. Monogram Announces Presentation of Clinical Data for the HERmark(TM) Breast Cancer Assay at the 44th ASCO Annual Meeting
7. Monogram Announces HERmark(TM) Oral Presentation at the 44th ASCO Annual Meeting
8. Monogram Biosciences Announces First Quarter 2008 Financial Results Conference Call
9. Monogram Biosciences to Present at the JMP Securities Seventh Annual Research Conference
10. Raven biotechnologies Announces Collaboration With Monogram Biosciences to Advance Diagnostic Cancer Technologies
11. Monogram HIV Antibody Assay Is Key Component of Innovative Vaccine Development Program

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2009)...HANGHAI, Dec. 1 /PRNewswire-Asia/ -- Shanghai Chem..., a leading China-based Contract Research,Organiza...2009 Deloitte,Technology Fast 50 China, ranking 3r...panies in China. The award is a testament to ChemP...m 2006 to 2008. , The results of the 2009...
(Date:12/1/2009)...INGFIELD, Ill., Dec. 1 Prairie Hea...nce that it was recently awarded two statuettes at...v. 13 in New York City. The CLIO Healthcare Awards...the healthcare advertising industry and is an exte...recognized awards competitions for advertising, de...
(Date:12/1/2009)... Enterprise level storage is now available ...thout breaking the bank. , ...ww.pacsdrive.com ), a medical imaging software co...ible cloud storage service. The PacsDrive service ...rs to securely archive medical imaging in complian...
(Date:12/1/2009)... Congruent Software agrees to migrate their...accounting clients) to Synergy Business Solutions ... Seattle, WA (PRWEB) December 1, 2009 -- Syne...ired the Microsoft Dynamics SL practice of Congrue...ovider. The move was necessary due to a change in ...
Breaking Biology Technology:Shanghai ChemPartner Ranks 3rd among 2009 Deloitte Technology Fast 50 China Winning Companies 2Shanghai ChemPartner Ranks 3rd among 2009 Deloitte Technology Fast 50 China Winning Companies 3Prairie Heart Institute of Illinois Wins Two CLIO Healthcare Awards 2PacsDrive Announces Low Cost Medical Imaging Storage Service, Seeks to Alter Status Quo in Health Care IT 2Synergy Business Solutions Acquires the Microsoft Dynamics SL Practice of Congruent Software, Inc. 2Synergy Business Solutions Acquires the Microsoft Dynamics SL Practice of Congruent Software, Inc. 3
...allows new scientific and business development fle.... 15 /PRNewswire-FirstCall/ - Resverlogix Corp.,("...s redeemed USD$10,million or approximately 60% of ... McCaffrey, President and CEO of Resverlogix state... and challenging for companies,around the globe. T...
...all and webcast to begin after markets close at 2:...ET), IRVINE, Calif., Oct. 15 Masimo Corporation,...y and,Measure-Through-Motion- and-Low-Perfusion pu...d quarter financial results for the period ended,S...y, October 27, 2008., A conference call to review...
..., Oct. 15 Strategic Healthcare,Group LLC announce...ith the,American Red Cross to provide Strategic Bl...00 American Red Cross client hospitals across the ...ghly successful Strategic Blood,Management(TM) pro...Birmingham Hospital and Baptist Hospital in Pensac...
Other Biology Technology:Resverlogix Eliminates Sixty Percent of Remaining Debt 2Masimo to Report Third Quarter 2008 Financial Results on October 27, 2008 2American Red Cross Expands Agreement for Strategic Blood Management(TM) Services from Strategic Healthcare Group LLC 2
(Date:11/30/2009)...orsyth Institute, the University of Connecticut He...e used state-of-the-art technology to elucidate th...e bacterium which causes syphilis. The previously ... be shown in three dimensions. This provides the f...usly unknown features, which may help fight the sp...
(Date:11/30/2009)...German . , The DFG has approved the establis...of 1 January 2010. This decision was made recently... centres will initially be funded for four years w...t overhead funding for indirect costs will also be...topics range from modern prostheses to political r...
(Date:11/30/2009)...ists and engineers from two of the nation,s larges...her Dec. 7 with leading academicians to explore th...uch like moving oil through a pipeline, the heart ...ed clean, well-functioning pipes (or blood vessels...iciently. Both industries also are crucial to our ...
Breaking Biology News(10 mins):Scientists gain new understanding of disease-causing bacteria 2DFG approves funding for 17 new collaborative research centers 2DFG approves funding for 17 new collaborative research centers 3DFG approves funding for 17 new collaborative research centers 4DFG approves funding for 17 new collaborative research centers 5DFG approves funding for 17 new collaborative research centers 6DFG approves funding for 17 new collaborative research centers 7DFG approves funding for 17 new collaborative research centers 8DFG approves funding for 17 new collaborative research centers 9Similarities of pumping blood and oil examined 2Similarities of pumping blood and oil examined 3Results From Landmark PROSPECT Trial Demonstrate the Ability of Volcanos VH 28R 29 IVUS Imaging to Identify Plaques Most Likely to Cause Heart Attacks 58307 1Results From Landmark PROSPECT Trial Demonstrate the Ability of Volcanos VH 28R 29 IVUS Imaging to Identify Plaques Most Likely to Cause Heart Attacks 58307 2Results From Landmark PROSPECT Trial Demonstrate the Ability of Volcanos VH 28R 29 IVUS Imaging to Identify Plaques Most Likely to Cause Heart Attacks 58307 3Results From Landmark PROSPECT Trial Demonstrate the Ability of Volcanos VH 28R 29 IVUS Imaging to Identify Plaques Most Likely to Cause Heart Attacks 58307 4Results From Landmark PROSPECT Trial Demonstrate the Ability of Volcanos VH 28R 29 IVUS Imaging to Identify Plaques Most Likely to Cause Heart Attacks 58307 5Results From Landmark PROSPECT Trial Demonstrate the Ability of Volcanos VH 28R 29 IVUS Imaging to Identify Plaques Most Likely to Cause Heart Attacks 58307 6Results From Landmark PROSPECT Trial Demonstrate the Ability of Volcanos VH 28R 29 IVUS Imaging to Identify Plaques Most Likely to Cause Heart Attacks 58307 7Results from Abbotts PROSPECT Study Provide New Insight into Role of Vulnerable Plaque in Coronary Artery Disease 5062 1Results from Abbotts PROSPECT Study Provide New Insight into Role of Vulnerable Plaque in Coronary Artery Disease 5062 2Results from Abbotts PROSPECT Study Provide New Insight into Role of Vulnerable Plaque in Coronary Artery Disease 5062 3Results from Abbotts PROSPECT Study Provide New Insight into Role of Vulnerable Plaque in Coronary Artery Disease 5062 4Reportlinker Adds Whos Doing What in Molecular Diagnostics 3F Kalorama Emmes Survey of US Laboratories Report 58303 1Reportlinker Adds Whos Doing What in Molecular Diagnostics 3F Kalorama Emmes Survey of US Laboratories Report 58303 2Reportlinker Adds Whos Doing What in Molecular Diagnostics 3F Kalorama Emmes Survey of US Laboratories Report 58303 3Reportlinker Adds Whos Doing What in Molecular Diagnostics 3F Kalorama Emmes Survey of US Laboratories Report 58303 4Reportlinker Adds Whos Doing What in Molecular Diagnostics 3F Kalorama Emmes Survey of US Laboratories Report 58303 5Reportlinker Adds Whos Doing What in Molecular Diagnostics 3F Kalorama Emmes Survey of US Laboratories Report 58303 6Reportlinker Adds Whos Doing What in Molecular Diagnostics 3F Kalorama Emmes Survey of US Laboratories Report 58303 7Reportlinker Adds Whos Doing What in Molecular Diagnostics 3F Kalorama Emmes Survey of US Laboratories Report 58303 8Reportlinker Adds Whos Doing What in Molecular Diagnostics 3F Kalorama Emmes Survey of US Laboratories Report 58303 9Reportlinker Adds Whos Doing What in Molecular Diagnostics 3F Kalorama Emmes Survey of US Laboratories Report 58303 10Reportlinker Adds Whos Doing What in Molecular Diagnostics 3F Kalorama Emmes Survey of US Laboratories Report 58303 11Reportlinker Adds Whos Doing What in Molecular Diagnostics 3F Kalorama Emmes Survey of US Laboratories Report 58303 12Reportlinker Adds Whos Doing What in Molecular Diagnostics 3F Kalorama Emmes Survey of US Laboratories Report 58303 13Reportlinker Adds Whos Doing What in Molecular Diagnostics 3F Kalorama Emmes Survey of US Laboratories Report 58303 14Reportlinker Adds Whos Doing What in Molecular Diagnostics 3F Kalorama Emmes Survey of US Laboratories Report 58303 15Reportlinker Adds Whos Doing What in Molecular Diagnostics 3F Kalorama Emmes Survey of US Laboratories Report 58303 16Reportlinker Adds Whos Doing What in Molecular Diagnostics 3F Kalorama Emmes Survey of US Laboratories Report 58303 17
... by invitation to an international scientific meet..., to identify strategies for the control of the on...ocusts stripped fields of crops and trees of folia... and food supply loss. , Larry Vaughan, associate...est Management Collaborative Research Support Prog...
...urther evidence that environmental factors could b...ies, published online today (Thursday 28 April) in...man Reproduction, suggest that environmental pollu...g the X or Y (sex determining) chromosomes and tha...tive disorders. , A study by Swedish researchers[1...
...accurate imaging technique have shed light on the ...terial within living cells. The motors cooperate i...gaging in the brute-force tug of war many scientis...lar motors -- dynein and kinesin -- do not compete...me cargo in opposite directions," said Paul Selvin...
Other Biology News:Scientists discuss improved biopesticides for locust control in West Africa 2How the environment could be damaging men's reproductive health 2How the environment could be damaging men's reproductive health 3How the environment could be damaging men's reproductive health 4Molecular Motors Cooperate In Moving Cellular Cargo, Study Shows 2
Rat Anti-Gamma delta T Lymphocytes Monoclonal Antibody, Unconjugated, Clone MAC320 from BD Biosciences Pharmingen
TE Buffer from Upstate
TE Buffer Solution, 1X, pH 8.0, sterile, Molecular Biology Grade from Research Organics, Inc.
Xylene Resistant (X/R) Red System, 1000 Tests (SIGNET) from Covance Research Products, Inc
Biology Products: